基于超声影像组学早期预测乳腺癌患者新辅助化疗反应:一项系统评价与Meta分析
该系统评价与Meta分析纳入8项研究,评估基于超声的影像组学早期预测乳腺癌新辅助化疗反应的诊断效能;汇总敏感度0.87(95%CI 0.81-0.92)、特异度0.78(95%CI 0.72-0.83),平均RQS评分为12.88(占总分35.8%);作者认为超声影像组学可能是评估新辅助化疗反应的潜在辅助方法,但因数据有限且研究质量不高,需更多严格设计的多中心前瞻性研究确认。
要点
- 汇总敏感度0.87、特异度0.78,提示超声影像组学对早期预测新辅助化疗反应有较好判别能力。
- 阳性似然比4.02、阴性似然比0.16、诊断比值比25.17,辅助确认与排除效能均较可观。
- 纳入研究平均RQS仅12.88(占总分35.8%),方法学质量偏低,解读结果需谨慎。
核心结论
- 基于超声的影像组学可能是评估乳腺癌新辅助化疗反应的潜在重要辅助方法,但可用数据有限且纳入研究质量不高,需更多严格方法的多中心前瞻性研究确认。
研究设计与样本
- 系统评价与Meta分析,检索PubMed、Cochrane Library、Embase和Web of Science数据库截至2023年1月1日的文献,最终纳入8项研究;采用影像组学质量评分(RQS)和诊断准确性研究质量评价工具第2版(QUADAS-2)评估方法学质量,并汇总诊断效能。
诊断标准与关键数值
- 超声影像组学预测新辅助化疗反应的汇总敏感度0.87(95%CI 0.81-0.92)、特异度0.78(95%CI 0.72-0.83)、阳性似然比4.02(95%CI 3.18-5.08)、阴性似然比0.16(95%CI 0.10-0.25)、诊断比值比25.17(95%CI 15.10-41.95);纳入研究平均RQS评分12.88(占总分35.8%),范围8至19。
局限性
- 可用数据有限且纳入研究质量不高。
- 需更多严格方法的多中心前瞻性研究确认上述发现。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: This study aims to evaluate the diagnostic accuracy of ultrasound imaging (US)-based radiomics for the early prediction of response to neoadjuvant chemotherapy (NAC) in breast cancer patients.
METHODS: We comprehensively searched PubMed, Cochrane Library, Embase, and Web of Science databases up to 1 January 2023 for eligible studies. We assessed the methodological quality of the enrolled studies with Radiomics Quality Score (RQS) and the Quality Assessment of Diagnostic Accuracy Studies-2 tools. We performed meta-analyses to summarize the diagnostic efficacy of US-based radiomics in response to NAC in breast cancer patients.
RESULTS: Eight studies proved eligible. Eligible studies exhibited an average RQS score of 12.88 (35.8% of the total score), with the RQS score ranging from 8 to 19. In the meta-analyses, the pooled sensitivity, specificity, positive likelihood ratio, negative likelihood ratio, and diagnostic odds ratio were 0.87 (95% CI 0.81-0.92), 0.78 (95% CI 0.72-0.83), 4.02 (95% CI 3.18-5.08), 0.16 (95% CI 0.10-0.25), and 25.17 (95% CI 15.10-41.95), respectively. Results from subgroup analyses indicated that prospective studies apparently exhibited more optimal sensitivity than retrospective studies. Sensitivity analyses exhibited similar results to the primary analyses.
CONCLUSION: US-based radiomics may be a potentially crucial adjuvant method for evaluating the response of breast cancer to NAC. Due to limited data available and low quality of eligible studies, more multicenter prospective studies with rigorous methods are required to confirm our findings.
引用
- Li Z, Liu X, Gao Y, et al. Ultrasound-based radiomics for early predicting response to neoadjuvant chemotherapy in patients with breast cancer: a systematic review with meta-analysis. Radiol Med. 2024. PMID: 38630147. doi:10.1007/s11547-024-01783-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。